$CTSO
Cytosorbents Corp Stock $ctso

$ctso Overview Financials Valuation SEC Filings Company Website

2015 Q3 Form 10-Q Financial Statement

#000114420415049003 Filed on August 13, 2015

Income Statement

Concept	2015 Q3	2015 Q2	2014 Q2
Revenue	$1.344M	$963.9K	$1.025M
YoY Change	15.6%	-5.93%	251.53%
Cost Of Revenue	$638.8K	$465.4K	$666.2K
YoY Change	34.24%	-30.13%	233.82%
Gross Profit	$704.8K	$498.5K	$358.5K
YoY Change	2.67%	39.05%	289.98%
Gross Profit Margin	52.45%	51.72%	34.99%
Selling, General & Admin	$1.700M	$1.626M	$1.209M
YoY Change	37.04%	34.53%	101.21%
% of Gross Profit	241.21%	326.25%	337.21%
Research & Development	$866.3K	$801.7K	$347.0K
YoY Change	-1.59%	131.03%	-51.0%
% of Gross Profit	122.92%	160.81%	96.79%
Depreciation & Amortization	$40.00K	$20.00K	$30.00K
YoY Change	100.0%	-33.33%	50.0%
% of Gross Profit	5.68%	4.01%	8.37%
Operating Expenses	$2.855M	$2.726M	$1.722M
YoY Change	31.57%	58.31%	14.89%
Operating Profit	-$2.150M	-$2.227M	-$1.363M
YoY Change	44.94%	63.38%	-3.09%
Interest Expense	$3.190K	$3.039K	-$127.8K
YoY Change	-106.85%	-102.38%	1468.3%
% of Operating Profit
Other Income/Expense, Net	-$697.1K	$3.662M	-$490.2K
YoY Change	4611.39%	-846.98%	5917.1%
Pretax Income	-$2.847M	$1.434M	-$1.854M
YoY Change	90.04%	-177.38%	31.0%
Income Tax	$0.00	$0.00
% Of Pretax Income		0.0%
Net Earnings	-$2.847M	$1.434M	-$1.854M
YoY Change	90.04%	-177.38%	31.0%
Net Earnings / Revenue	-211.92%	148.8%	-180.9%
Basic Earnings Per Share	-$0.11	$0.06	-$0.27
Diluted Earnings Per Share	-$0.11	$0.05	-$0.27
COMMON SHARES
Basic Shares Outstanding	25.05M shares	24.77M shares	12.05M shares
Diluted Shares Outstanding		28.83M shares	12.05M shares

Balance Sheet

Concept	2015 Q3	2015 Q2	2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$9.300M	$11.20M	$9.600M
YoY Change	19.23%	16.67%	405.26%
Cash & Equivalents	$7.386M	$8.017M	$4.878M
Short-Term Investments	$1.900M	$3.200M	$4.700M
Other Short-Term Assets	$400.0K	$300.0K	$400.0K
YoY Change	100.0%	-25.0%	100.0%
Inventory	$1.300M	$1.060M	$303.7K
Prepaid Expenses
Receivables	$553.4K	$500.0K	$300.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$11.60M	$13.04M	$10.62M
YoY Change	29.54%	22.77%	310.62%
LONG-TERM ASSETS
Property, Plant & Equipment	$500.0K	$402.8K	$172.0K
YoY Change	161.61%	134.21%	20.54%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$700.0K	$655.2K	$462.6K
YoY Change	45.53%	41.63%	83.98%
Total Long-Term Assets	$1.200M	$1.058M	$634.6K
YoY Change	78.53%	66.72%	61.02%
TOTAL ASSETS
Total Short-Term Assets	$11.60M	$13.04M	$10.62M
Total Long-Term Assets	$1.200M	$1.058M	$634.6K
Total Assets	$12.80M	$14.10M	$11.26M
YoY Change	32.96%	25.25%	277.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$500.0K	$417.7K	$526.0K
YoY Change	12.07%	-20.58%	-27.01%
Accrued Expenses	$800.0K	$700.0K	$600.0K
YoY Change	100.0%	16.67%	20.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due			$700.0K
YoY Change			-22.22%
Total Short-Term Liabilities	$3.400M	$2.528M	$2.769M
YoY Change	119.43%	-8.72%	31.62%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.400M	$2.528M	$2.769M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$3.400M	$2.500M	$2.800M
YoY Change	126.67%	-10.71%	33.08%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock			$310.4K
YoY Change			32.42%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$9.400M	$11.60M	-$9.230M
YoY Change
Total Liabilities & Shareholders Equity	$12.80M	$14.10M	$11.26M
YoY Change	32.96%	25.26%	277.62%

Cashflow Statement

Concept	2015 Q3	2015 Q2	2014 Q2
OPERATING ACTIVITIES
Net Income	-$2.847M	$1.434M	-$1.854M
YoY Change	90.04%	-177.38%	31.0%
Depreciation, Depletion And Amortization	$40.00K	$20.00K	$30.00K
YoY Change	100.0%	-33.33%	50.0%
Cash From Operating Activities	-$2.260M	-$2.600M	-$1.460M
YoY Change	17.1%	78.08%	43.14%
INVESTING ACTIVITIES
Capital Expenditures	-$180.0K	-$100.0K	-$90.00K
YoY Change	200.0%	11.11%	125.0%
Acquisitions
YoY Change
Other Investing Activities	$1.240M	-$250.0K	$0.00
YoY Change	-147.69%
Cash From Investing Activities	$1.060M	-$350.0K	-$90.00K
YoY Change	-139.7%	288.89%	125.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	560.0K	470.0K	10.00K
YoY Change	1766.67%	4600.0%	-99.36%
NET CHANGE
Cash From Operating Activities	-2.260M	-2.600M	-1.460M
Cash From Investing Activities	1.060M	-350.0K	-90.00K
Cash From Financing Activities	560.0K	470.0K	10.00K
Net Change In Cash	-640.0K	-2.480M	-1.540M
YoY Change	-86.0%	61.04%	-408.0%
FREE CASH FLOW
Cash From Operating Activities	-$2.260M	-$2.600M	-$1.460M
Capital Expenditures	-$180.0K	-$100.0K	-$90.00K
Free Cash Flow	-$2.080M	-$2.500M	-$1.370M
YoY Change	11.23%	82.48%	39.8%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.47
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.90
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	0.06
CY2014Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	819151	USD
CY2014Q4	us-gaap	Inventory Net InventoryNet	537566	USD
CY2015Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	274544	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	700462	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8017344	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	833	USD
CY2015Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1392512	USD
CY2014Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	2981418	USD
CY2015Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2527890	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4505442	USD
CY2015Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q2	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2015Q2	us-gaap	Inventory Net InventoryNet	1059945	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	615798	USD
CY2015Q2	us-gaap	Assets Assets	14098864	USD
CY2014Q4	us-gaap	Assets Assets	8468625	USD
CY2015Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	417719	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	698307	USD
CY2015Q2	ctso	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	717659	USD
CY2014Q4	ctso	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	824884	USD
CY2015Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent		USD
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2015Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3605280	USD
CY2015Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24890521	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23304640	shares
CY2015Q2	us-gaap	Short Term Investments ShortTermInvestments	3188000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	3963183	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8468625	USD
CY2014Q4	us-gaap	Short Term Investments ShortTermInvestments	1944547	USD
CY2015Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	3728	USD
CY2014Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	3756	USD
CY2015Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23304640	shares
CY2015Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24890521	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1626398	USD
CY2014Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1208923	USD
CY2015Q2	us-gaap	Assets Current AssetsCurrent	13040875	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	7607006	USD
CY2015Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	402823	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	245821	USD
CY2015Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	655166	USD
CY2015Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet	501042	USD
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	1434318	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-1853602	USD
CY2015Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-76361	USD
CY2014Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	4318	USD
CY2015Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1357957	USD
CY2014Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1849284	USD
CY2015Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	773112	USD
CY2014Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	663233	USD
CY2015Q2	us-gaap	Revenue From Grants RevenueFromGrants	179657	USD
CY2014Q2	us-gaap	Revenue From Grants RevenueFromGrants	358922	USD
CY2015Q2	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	11170	USD
CY2014Q2	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	2500	USD
CY2015Q2	us-gaap	Sales Revenue Net SalesRevenueNet	963939	USD
CY2014Q2	us-gaap	Sales Revenue Net SalesRevenueNet	1024655	USD
CY2015Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	465431	USD
CY2014Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	666151	USD
CY2015Q2	us-gaap	Gross Profit GrossProfit	498508	USD
CY2014Q2	us-gaap	Gross Profit GrossProfit	358504	USD
CY2015Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	801656	USD
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	346993	USD
CY2015Q2	us-gaap	Professional Fees ProfessionalFees	297913	USD
CY2014Q2	us-gaap	Professional Fees ProfessionalFees	165977	USD
CY2015Q2	us-gaap	Operating Expenses OperatingExpenses	2725967	USD
CY2014Q2	us-gaap	Operating Expenses OperatingExpenses	1721893	USD
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2227459	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1363389	USD
CY2014Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-127769	USD
CY2015Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	3039	USD
CY2015Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-3596832	USD
CY2014Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	342720	USD
CY2015Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3661777	USD
CY2014Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-490213	USD
CY2015Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	1434318	USD
CY2014Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1853602	USD
CY2015Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
CY2014Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
CY2015Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact		USD
CY2014Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1374245	USD
CY2015Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1434318	USD
CY2014Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3227847	USD
CY2015Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.06
CY2014Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.27
CY2015Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24768639	shares
CY2014Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12047838	shares
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1476770	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1232476	USD
	us-gaap	Revenue From Grants RevenueFromGrants	198240	USD
	us-gaap	Revenue From Grants RevenueFromGrants	850184	USD
	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	12003	USD
	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	4167	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	1687013	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	2086827	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	769912	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1328688	USD
	us-gaap	Gross Profit GrossProfit	917101	USD
	us-gaap	Gross Profit GrossProfit	758139	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1752684	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	583767	USD
	us-gaap	Professional Fees ProfessionalFees	513431	USD
	us-gaap	Professional Fees ProfessionalFees	402510	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3141565	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2277877	USD
	us-gaap	Operating Expenses OperatingExpenses	5407680	USD
	us-gaap	Operating Expenses OperatingExpenses	3264154	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4490579	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2506015	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	5652	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-264858	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1588906	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	26520	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1207955	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-322670	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-3282624	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-2828685	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
	us-gaap	Net Income Loss NetIncomeLoss	-3282624	USD
	us-gaap	Net Income Loss NetIncomeLoss	-2828685	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact		USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	2488761	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3282624	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5317446	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24582590	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11336984	shares
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	267818	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	5151	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3014806	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2823534	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-386603	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-31292	USD
CY2015Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	61906	USD
CY2014Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-19724	USD
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.47
CY2015Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.05
CY2014Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.27
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24582590	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11336984	shares
CY2015Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28826158	shares
CY2014Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12047838	shares
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	146428	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	9408584	USD
	ctso	Stock Issued During Period Value Stock Warrants Exercised StockIssuedDuringPeriodValueStockWarrantsExercised		USD
	ctso	Stock Issued During Period Value Stock Cash Warrants Exercised StockIssuedDuringPeriodValueStockCashWarrantsExercised	818250	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		USD
	ctso	Stock Issued During Period Value Stock Cash Options Exercised StockIssuedDuringPeriodValueStockCashOptionsExercised	249335	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	90100	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	44428	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	45596	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	162982	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	146428	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	104858	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-284278	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-122670	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	496208	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	58078	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-416932	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-240348	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	7134	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	4912	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-360356	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	104326	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-833	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-266526	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4559026	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2260801	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	192554	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	54734	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	45402	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	61760	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	2442547	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments		USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	3686000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	4745000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1481409	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4861494	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9408584	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9751455	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	249335	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	61105	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	818250	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10476169	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9812560	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-23670	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	5151	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	4412064	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	2695416	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2183030	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4878446	USD
	us-gaap	Interest Paid InterestPaid		USD
	us-gaap	Interest Paid InterestPaid		USD
	ctso	Fair Value Warrant Liability Upon Issuance FairValueWarrantLiabilityUponIssuance		USD
	ctso	Fair Value Warrant Liability Upon Issuance FairValueWarrantLiabilityUponIssuance	862920	USD
	us-gaap	Stock Issued1 StockIssued1		USD
	us-gaap	Stock Issued1 StockIssued1	7137	USD
	ctso	Supplemental Noncash Transactions SupplementalNoncashTransactions	903916	USD
	ctso	Supplemental Noncash Transactions SupplementalNoncashTransactions	748545	USD
	us-gaap	Freight Costs FreightCosts	48000	USD
	ctso	Preferred Dividends Accrued Not Yet Paid PreferredDividendsAccruedNotYetPaid		USD
	ctso	Preferred Dividends Accrued Not Yet Paid PreferredDividendsAccruedNotYetPaid	2488761	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-284969	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized		USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1185840	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1		USD
	us-gaap	Basis Of Accounting BasisOfAccounting	<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <div class="CursorPointer"> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px"><font style="font-size: 10pt"><b>1.</b></font></td> <td style="text-align: justify"><font style="font-size: 10pt"><b>BASIS OF PRESENTATION</b></font></td></tr> </table> </div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in;"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">The Company's interim financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP). In the opinion of management, the Company has made all necessary adjustments, which include normal recurring adjustments necessary for a fair statement of the Company's financial position and results of operations for the interim periods presented. Certain information and disclosures normally included in the annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. These interim financial statements should be read in conjunction with the audited financial statements and accompanying notes for the year ended December 31, 2014 included in the Company's Annual Report on Form 10-K. The results for the three months and six months ended June 30, 2015 are not necessarily indicative of the results to be expected for a full year, any other interim periods or any future year or period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in;"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company believes that it has adequate funding for more than the next twelve months of operations, however, it may have to raise additional capital to fund its future operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">As of June 30, 2015, the Company had an accumulated deficit of $<font>127,676,744</font>, which included net losses of $<font>3,282,624</font> for the six months ended June 30, 2015 and $<font>2,828,685</font> for the six months ended June 30, 2014. <font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333330154419px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;">The Company's losses have resulted principally from costs incurred in the research and development of the Company's polymer technology and selling, general and administrative expenses. The Company intends to continue to conduct significant additional research, development, and clinical study activities which, together with expenses incurred for the establishment of manufacturing arrangements and a marketing and distribution presence and other selling, general and administrative expenses, are expected to result in continuing operating losses for the foreseeable future. The amount of future losses and when, if ever, the Company will achieve profitability are uncertain. The Company's ability to achieve profitability will depend, among other things, on successfully completing the development of the Company's technology and commercial products, obtaining additional requisite regulatory approvals in markets not covered by the CE Mark and for potential label extensions of the Company's current CE Mark, establishing manufacturing and sales and marketing arrangements with third parties, and raising sufficient funds to finance the Company's activities. No assurance can be given that the Company's product development efforts will be successful, that the Company's current CE Mark will enable us to achieve profitability, that additional regulatory approvals in other countries will be obtained, that any of the Company's products will be manufactured at a competitive cost and will be of acceptable quality, or that the Company will be able to achieve profitability or that profitability, if achieved, can be sustained. These matters raise substantial doubt about the Company's ability to continue as a going concern. These consolidated financial statements do not include any adjustments related to the outcome of this uncertainty.</font></p> </div>
CY2014Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	25	pure
CY2015Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	290826	USD
CY2014Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	142693	USD
CY2015Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	692815	USD
CY2014Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	326047	USD
CY2015Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	76304	USD
CY2014Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	68826	USD
	us-gaap	Advertising Expense AdvertisingExpense	117000	USD
	us-gaap	Advertising Expense AdvertisingExpense	64000	USD
	us-gaap	Freight Costs FreightCosts	67000	USD
CY2015Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10312500	USD
CY2015Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9409000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"><b>Use of Estimates</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities. Actual results could differ from these estimates. Significant estimates in these financials are the valuation of options granted, the valuation of preferred shares issued as stock dividends and valuation methods used to determine the fair value of the warrant liability.</p> </div>
CY2015Q1	ctso	Underwriters Expenses UnderwritersExpenses	85000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	146000	USD
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"><b>Concentration of Credit Risk</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">The Company maintains cash balances, at times, with financial institutions in excess of amounts insured by the Federal Deposit Insurance Corporation. Management monitors the soundness of these institutions in an effort to minimize its collection risk of these balances.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">As of June 30, 2015, <font>three</font> distributors accounted for approximately <font>61</font>% of outstanding grant and accounts receivable. At December 31, 2014, <font>three</font> distributors accounted for approximately <font>53</font>% of outstanding grant and accounts receivable. For the six months ended June 30, 2015, approximately <font>12</font>% of revenues was from <font>one</font> <font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333330154419px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;">U.S. government grant agency</font>. No other agency, distributor, or direct customer represented more than 10% of the Company's revenue. For the six months ended June 30, 2014, approximately <font>12</font>% of revenues were from <font>one</font> U.S. government grant agency, and no other agency, distributor, or direct customer represented more than 10% of the Company's revenue.</p> </div>
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2302187	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.37
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y1M6D
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"><b>Reclassifications</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;">Certain reclassifications have been made to the June 30, 2014 financial statements in order to conform to the June 30, 2015 financial statement presentation. There was no change in the reported amount of the accumulated deficit as a result of these reclassifications.</p> </div>
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	626000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.98
	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Granted In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm	P9Y7M6D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	150779	shares
	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageRemainingContractualTerm	P8Y9M18D
CY2015Q2	us-gaap	Advertising Expense AdvertisingExpense	66000	USD
CY2014Q2	us-gaap	Advertising Expense AdvertisingExpense	53000	USD
CY2015Q2	us-gaap	Freight Costs FreightCosts	26000	USD
CY2014Q2	us-gaap	Freight Costs FreightCosts	25000	USD
	us-gaap	Dividends Preferred Stock Stock DividendsPreferredStockStock	2488761	USD
CY2015Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1250000	shares
CY2015Q1	us-gaap	Share Price SharePrice	8.25
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	138034	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.22
	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm	P3Y10M24D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2639374	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.18
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y4M24D
CY2014Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	874530	shares
CY2014Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	1.37
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	626000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.26
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	150779	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	0.06
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	424326	shares
CY2015Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	925425	shares
CY2015Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	2.22
CY2015Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	406000	USD
CY2015Q2	ctso	Share Based Compensation Arrangement By Share Based Payment Award Non Vested Options Vested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonVestedOptionsVestedNumber	566000	shares
CY2015Q2	ctso	Share Based Compensation Arrangement By Sharebased Payment Award Nonvested Options Grant Date Fair Value ShareBasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsGrantDateFairValue	1388000	USD
CY2015Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1418145	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1713949	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	5.82
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y2M12D
CY2015Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	83000	USD
CY2014Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	816000	shares
CY2014Q1	ctso	Fair Value Warrant Liability Upon Issuance FairValueWarrantLiabilityUponIssuance	862920	USD
CY2014Q1	us-gaap	Share Price SharePrice	6.00
CY2015Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	736000	shares
CY2014Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	816000	shares
CY2015Q2	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	4058000	shares
	dei	Entity Registrant Name EntityRegistrantName	Cytosorbents Corp
	dei	Entity Central Index Key EntityCentralIndexKey	0001175151
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2015-06-30
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2015Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	25046990	shares
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Trading Symbol TradingSymbol	ctso

Files In Submission

Name	View Source	Status
0001144204-15-049003-index-headers.html	Edgar Link	pending
0001144204-15-049003-index.html	Edgar Link	pending
0001144204-15-049003.txt	Edgar Link	pending
0001144204-15-049003-xbrl.zip	Edgar Link	pending
ctso-20150630.xml	Edgar Link	completed
ctso-20150630.xsd	Edgar Link	pending
ctso-20150630_cal.xml	Edgar Link	unprocessable
ctso-20150630_def.xml	Edgar Link	unprocessable
ctso-20150630_lab.xml	Edgar Link	unprocessable
ctso-20150630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v416929_10q.htm	Edgar Link	pending
v416929_ex31-1.htm	Edgar Link	pending
v416929_ex31-2.htm	Edgar Link	pending
v416929_ex32-1.htm	Edgar Link	pending
v416929_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CTSO
Cytosorbents Corp Stock $ctso

2015 Q3 Form 10-Q Financial Statement

#000114420415049003 Filed on August 13, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CTSO Cytosorbents Corp Stock $ctso

2015 Q3 Form 10-Q Financial Statement

#000114420415049003 Filed on August 13, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CTSO
Cytosorbents Corp Stock $ctso